ITGAM and neoplasm: In tumor-bearing lungs, AMs adopt an activated phenotype, marked by upregulation of CD11b, downregulation of Siglec-F expression, elevated expression of inflammatory genes, and enhanced phagocytic, efferocytotic, and anti-tumor activity (Supplementary Figure S7).